PLAGL2 Activators
PLAGL2 Activators are a collection of chemical compounds that indirectly augment the functional activity of PLAGL2 through diverse signaling pathways. Forskolin and IBMX raise intracellular cAMP levels, indirectly boosting PLAGL2 activity by activating PKA, which may phosphorylate proteins within PLAGL2's sphere of influence, particularly in the context of cellular regulation. This enhancement of PLAGL2's regulatory role is further supported by Epigallocatechin Gallate, a kinase inhibitor which suppresses competitive signaling pathways, potentially leading to a more pronounced activity of PLAGL2 in transcriptional control. Similarly, LY294002, a PI3K inhibitor, and Rapamycin, an mTOR inhibitor, can indirectly enhance PLAGL2's involvement in cellular growth regulation by altering downstream signaling cascades.
In addition to these, PD98059 and U0126, which inhibit components of the MAPK pathway, can indirectly facilitate the upregulation of PLAGL2's regulatory functions in cell proliferation and differentiation by diminishing competing signaling processes. The activity of PLAGL2 is also potentially enhanced by Y-27632, a ROCK inhibitor, and SB203580, a p38 MAPK inhibitor, which modulate pathways associated with stress response and cytoskeletal dynamics that PLAGL2 may intersect with. A23187 and Thapsigargin, which influence intracellular calcium levels, and Sphingosine-1-phosphate, a bioactive lipid, further contribute to the activation of signaling pathways that can enhance the functional activity of PLAGL2 in processes such as apoptosis and cell morphology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin increases intracellular cAMP, which can activate PKA. PKA can then phosphorylate proteins that are involved in the same cellular processes as PLAGL2, potentially enhancing PLAGL2's activity in cell regulation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, which increases cAMP by preventing its breakdown. The elevated cAMP levels can stimulate PKA activity, influencing pathways that PLAGL2 is a part of, thereby enhancing its activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a kinase inhibitor, which can alter signaling pathways by inhibiting competitive pathways, potentially leading to the enhanced activity of PLAGL2 in its role in transcriptional regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can lead to alterations in the AKT signaling pathway, indirectly affecting transcription factors and processes that PLAGL2 is involved with, thereby enhancing its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a part of the PI3K/AKT pathway. This inhibition can lead to changes in cellular growth processes, potentially influencing PLAGL2's activity in cell growth regulation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an MEK inhibitor, which can indirectly affect the pathways that PLAGL2 influences by altering the MAPK pathway, potentially enhancing PLAGL2's role in the control of cell proliferation and differentiation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, leading to changes in cytoskeletal dynamics. This can influence signaling pathways that PLAGL2 is involved in, potentially enhancing PLAGL2's activity in cell morphology and motility. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which may enhance PLAGL2's activity by modulating the cellular stress response pathways that PLAGL2 is associated with. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, potentially enhancing PLAGL2's activity by affecting calcium-dependent signaling pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to increased cytosolic calcium levels, potentially enhancing PLAGL2's function by activating calcium-dependent signaling pathways. | ||||||